PRNB Insider Trading
PRNB | Market Equity
Comprehensive Trading Performance Summary
The investment history of corporate insiders at PRNB provides a unique lens into the internal conviction of the company's leadership. By analyzing SEC Form 4 filings, investors can track how directors and officers are allocating their own capital. High-conviction buying often signals that management believes the current market price significantly undervalues future growth prospects, while strategic selling might occur for personal liquidity or portfolio diversification. Monitoring these shifts in ownership is essential for understanding the alignment between management and shareholders in the Market Equity sector.
Transactions on Chart
Open Full Chart| Filing Date | Trade Date | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|
| 2020-09-23 03:02 | 2020-09-18 | Hardiman Roy C. | Officer - Chief Business Officer | OPT+S | $99.98 | 5,000 | $499,918 | 117,761 | 0.0% |
| 2020-08-21 03:17 | 2020-08-18 | Thomas Dolca | Officer - Chief Medical Officer | OPT+S | $100.00 | 15,000 | $1,500,000 | 1,826 | 0.0% |
| 2020-08-21 03:01 | 2020-08-18 | CHAI CHRISTOPHER Y | Officer - Chief Financial Officer | OPT+S | $99.37 | 7,500 | $745,240 | 3,539 | 0.0% |
| 2020-08-13 03:01 | 2020-08-10 | Goldstein David M | Officer - Chief Scientific Officer | OPT+S | $88.61 | 6,000 | $531,665 | 31,739 | 0.0% |
| 2020-07-18 03:01 | 2020-07-15 | Thomas Dolca | Officer - Chief Medical Officer | OPT+S | $80.07 | 15,000 | $1,201,070 | 1,826 | 0.0% |
| 2020-07-03 03:48 | 2020-07-01 | Colowick Alan | Director | OPT+S | $60.00 | 7,500 | $450,000 | 0 | 0.0% |
| 2020-06-26 03:07 | 2020-06-23 | Babler Martin | Director, Officer - President, CEO | OPT+S | $61.86 | 15,000 | $927,888 | 810 | 0.0% |
| 2020-06-18 04:52 | 2020-06-15 | Wolff Stefani | Officer - Chief Development Officer | SELL | $60.75 | 5,504 | $334,385 | 19,096 | -22.4% |
| 2020-06-18 04:48 | 2020-03-16 | Wolff Stefani | Officer - Chief Development Officer | SELL | $46.15 | 5,504 | $254,031 | 24,600 | -18.3% |
| 2020-06-18 04:41 | 2019-12-16 | Wolff Stefani | Officer - Chief Development Officer | SELL | $49.43 | 5,505 | $272,091 | 30,104 | -15.5% |
| 2020-06-16 03:12 | 2020-06-12 | Hardiman Roy C. | Officer - Chief Business Officer | OPT+S | $61.16 | 5,000 | $305,789 | 117,761 | 0.0% |
| 2020-05-22 03:01 | 2020-05-19 | CHAI CHRISTOPHER Y | Officer - Chief Financial Officer | OPT+S | $65.10 | 7,500 | $488,268 | 3,539 | 0.0% |
| 2020-05-09 03:05 | 2020-05-07 | Goldstein David M | Officer - Chief Scientific Officer | OPT+S | $60.16 | 6,000 | $360,941 | 30,968 | 0.0% |
| 2020-05-06 03:07 | 2020-05-01 | Colowick Alan | Director | OPT+S | $60.01 | 7,500 | $450,057 | 0 | 0.0% |
| 2020-03-19 00:08 | 2020-03-16 | Wolff Stefani | Officer - Chief Development Officer | OPT+S | $46.15 | 5,504 | $254,031 | 35,609 | 0.0% |
| 2020-03-18 00:08 | 2020-03-13 | Hardiman Roy C. | Officer - Chief Business Officer | OPT+S | $48.56 | 5,000 | $242,816 | 116,903 | 0.0% |
| 2020-03-06 01:21 | 2020-03-03 | Babler Martin | Director, Officer - President, CEO | SELL | $63.47 | 15,000 | $952,083 | 39,179 | -27.7% |
| 2020-02-21 01:02 | 2020-02-18 | CHAI CHRISTOPHER Y | Officer - Chief Financial Officer | OPT+S | $65.89 | 7,500 | $494,186 | 4,766 | 0.0% |
| 2020-02-13 03:03 | 2020-02-10 | Goldstein David | Officer - Chief Scientific Officer | OPT+S | $70.90 | 6,000 | $425,400 | 30,968 | 0.0% |
| 2019-12-21 05:00 | 2019-12-19 | Thomas Dolca | Officer - Chief Medical Officer | SELL | $60.00 | 495 | $29,700 | 494 | -50.1% |
| 2019-12-20 05:06 | 2019-12-17 | Babler Martin | Director, Officer - President, CEO | SELL | $53.07 | 29,500 | $1,565,456 | 15,696 | -65.3% |
| 2019-12-19 03:09 | 2019-12-16 | Wolff Stefani | Officer - Chief Development Officer | OPT+S | $49.43 | 5,505 | $272,091 | 35,609 | 0.0% |
| 2019-12-14 04:04 | 2019-12-13 | Hardiman Roy C. | Officer - Chief Business Officer | OPT+S | $49.41 | 5,000 | $247,034 | 120,143 | 0.0% |
| 2019-11-23 04:07 | 2019-11-20 | Becker Daniel J. | Director | BUY | $29.94 | 55,000 | $1,646,700 | 667,600 | +9.0% |
| 2019-11-09 05:01 | 2019-11-07 | Goldstein David | Officer - Chief Scientific Officer | OPT+S | $32.39 | 10,000 | $323,914 | 29,819 | 0.0% |
| 2019-10-30 23:16 | 2019-10-28 | Becker Daniel J. | Director | BUY | $33.48 | 77,600 | $2,598,025 | 612,600 | +14.5% |
| 2019-10-22 23:11 | 2019-10-18 | George Simeon | Director | BUY | $28.00 | 357,142 | $9,999,976 | 2,982,855 | +13.6% |
| 2019-10-22 23:06 | 2019-10-18 | Becker Daniel J. | Director | BUY | $28.00 | 535,000 | $14,980,000 | 535,000 | +100.0% |
| 2019-10-23 00:36 | 2019-10-18 | GLAXOSMITHKLINE PLC | Other | BUY | $28.00 | 357,142 | $9,999,976 | 2,982,855 | +13.6% |
| 2019-08-15 23:47 | 2019-08-13 | New Leaf Ventures II, L.P. | 10% owner | SELL | $35.00 | 300,000 | $10,500,000 | 387,546 | -43.6% |
| 2019-05-22 19:43 | 2019-05-21 | ORBIMED ADVISORS LLC | 10% owner | SELL | $30.25 | 1,000,000 | $30,250,000 | 1,605,713 | -38.4% |
| 2018-09-21 01:58 | 2018-09-18 | Becker Daniel J. | Director, 10% owner | BUY | $17.00 | 270,000 | $4,590,000 | 437,537 | +161.2% |
| 2018-09-21 01:50 | 2018-09-18 | George Simeon | Director, 10% owner | BUY | $17.00 | 270,000 | $4,590,000 | 2,625,713 | +11.5% |
| 2018-09-21 01:53 | 2018-09-18 | New Leaf Ventures II, L.P. | 10% owner | BUY | $17.00 | 270,000 | $4,590,000 | 437,537 | +161.2% |
| 2018-09-20 23:14 | 2018-09-18 | AKKARAJU SRINIVAS | Director | BUY | $17.00 | 175,000 | $2,975,000 | 383,480 | +83.9% |
| 2018-09-21 02:02 | 2018-09-18 | Sofinnova Venture Partners VIII, L.P. | 10% owner | BUY | $17.00 | 270,000 | $4,590,000 | 2,038,208 | +15.3% |
| 2018-09-21 00:18 | 2018-09-18 | GLAXOSMITHKLINE PLC | 10% owner | BUY | $17.00 | 270,000 | $4,590,000 | 2,625,713 | +11.5% |
| 2018-09-21 01:59 | 2018-09-18 | ORBIMED ADVISORS LLC | 10% owner | BUY | $17.00 | 250,000 | $4,250,000 | 2,605,713 | +10.6% |
How to Interpret $PRNB Trades
Not every insider transaction in PRNB is a signal for immediate action. Professional investors look for "cluster buying"—when multiple executives simultaneously purchase $PRNB shares on the open market. It is crucial to distinguish between scheduled sales (under Rule 10b5-1) and voluntary increases in ownership, which demonstrate management’s true conviction that the stock is undervalued.
Data Source & Accuracy for PRNB
Insider activity data for PRNB is streamed in real-time directly from the SEC EDGAR system. We analyze raw Form 4 filings, filtering out technical adjustments and complex derivative transactions. This provides a transparent view of how ownership structure is evolving in $PRNB, allowing you to follow the capital of those with the most intimate knowledge of the company.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.